Track topics on Twitter Track topics that are important to you
Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics
Although the pharmaceutical market is continuing to witness global growth, pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market, such as increasing costs of production and RD, shifts in patent laws, and challenges in the economy. Companies are considering various strategies to overcome these challenges, with deal making being foremost among these as a means of boosting revenues over a short period of time.
Small companies that primarily carry out earlystage research, development and production activities are entering into agreements with key industry leaders to outlicense the rights to their products, utilizing the strengths of the larger companies in terms of commercialization expertise, manufacturing, distribution and marketing capabilities and global presence. Additionally, many companies have successfully implemented dealmaking strategies to secure extended protection for their products from generic competitors. Deal activity can help pharma companies to enhance their research and regulatory approaches, and can aid portfolio expansion and diversification, geographic expansion, entry into niche markets, commercialization, and sales.
This report analyzes the importance of deal making in the pharmaceutical and healthcare market. It covers key factors that encourage deal activity in the pharmaceutical industry, and the key strategies being implemented when companies strike deals. An overview of recent deal activity from 2010 to May 2017 is also included.
What deal making strategies have been used in recent years to boost RD productivity and allow the successful commercialization of pharmaceutical products?
In which geographical markets and disease areas has deal activity been focused since 2010?
At which stage of development did deals most frequently occur, and attract the highest value?
How have pharma companies been using deal making to strengthen their product portfolio and bottom line?
What are the most significant Mergers and Acquisitions MAs, licensing deals and partnership deals to have been announced since 2016?
Who are the major players in pharmaceutical deal making, and what has been their recent and key deal activity?
Key Reasons to Purchase
Gain a comprehensive understanding of the most recent healthcare deal trends.
Understand the most significant MAs, licensing deals and partnerships to have occurred in recent years.
Comprehensively analyze the trends of deal activity from 2010 to May 2017, with respect to aggregate deal value, geography, and the therapy area and stage of development of the products involved.
Understand the dealmaking strategies that have been historically implemented by companies, and identify the most suitable strategies for boosting RD portfolio and bottom line performance.
Identify the key deal terminations that have occurred in recent years, and understand their effect.
Original Article: Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics [Report Updated: 01072017] Prices from USD $2995NEXT ARTICLE
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...